City

Bron (1)

Guangzhou (1)

Tokyo, Sumida-ku (1)

Condition

Healthy (1)

Menorrhagia (1)

Type 2 Diabetes Mellitus (1)

Overall Status

Recruiting (2)

Completed (1)

Phase

n/a (1)

phase 1 (1)

phase 4 (1)

Sponsor

Boehringer Ingelheim (1)

Hospices Civils de Lyon (1)

Sun Yat-sen University (1)

Collaborator

Guangdong Provincial Hospital of Traditional Chinese Medicine (1)

Guangdong Provincial People's Hospital (1)

Guangzhou First People's Hospital (1)

Nanfang Hospital of Southern Medical University (1)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)

The Third Affiliated Hospital of Guangzhou Medical University (1)

The Third Affiliated Hospital of Southern Medical University (1)

Zhujiang Hospital (1)

Intervention

csii alone (1)

csii followed by lina (1)

csii followed by lina+met (1)

csii followed by met (1)

empagliflozin/linagliptin fdc (1)

use of the lina libratatm (1)

Study Documents

Intervention Type

drug (2)

device (1)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (3)

Lina LibrataTM

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Menorrhagia Trial in Bron (Use of the Lina LibrataTM)

Recruiting

Menorrhagia

Use of the Lina LibrataTM

Bron, France

Hospices Civils de Lyon

Jan 4, 2023

Type 2 Diabetes Trial in Guangzhou (CSII followed by Lina+MET, CSII followed by Lina, CSII followed by MET)

Recruiting

Type 2 Diabetes Mellitus

CSII followed by Lina+MET
+3 more

Guangzhou, Guangdong, China

endocrinology department of the first affiliated hospital of Sun

Apr 28, 2021

Healthy Trial in Tokyo, Sumida-ku (empagliflozin/linagliptin FDC)

Completed

Has Results

Healthy

empagliflozin/linagliptin FDC

Tokyo, Sumida-ku, Japan

SOUSEIKAI Sumida Hospital

Oct 5, 2017